Based on the aforementioned research advancements and drug sensitivity analyses, we have chosen SAC3D1, currently understudied in hepatocellular carcinoma, as the focus for subsequent ex vivo experiments. This evidence concerns the gene SAC3D1 and hepatocellular carcinoma.